# Perrigo Company plc (PRGO) Stock Analysis: Evaluating a 31.61% Potential Upside in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-stock-analysis-evaluating-a-31-61-potential-upside-in-the-healthcare-sector/4121196964
- Published: 2025-05-16T10:11:52+01:00
- Author: Madison Wilson

Investors eyeing the healthcare sector should take a closer look at Perrigo Company
plc (NYSE: PRGO), a key player in the specialty and generic drug manufacturing industry.
Headquartered in Dublin, Ireland, Perrigo is known for its expansive portfolio of
over-the-counter health and wellness products, which it distributes across the United
States, Europe, and globally. As of now, the company holds a market capitalization
of $3.61 billion, positioning it as a significant contender in the healthcare market.

Currently trading at $26.29, Perrigo’s stock is near the midpoint of its 52-week
range of $23.50 to $30.10. While the stock price has shown modest movement with 
a recent 0.01% change, the company’s forward P/E ratio of 8.07 suggests potential
value for investors seeking growth opportunities. Analysts have set a target price
range of $27.00 to $42.00, with an average target of $34.60, indicating a potential
upside of 31.61%.

However, a closer examination of Perrigo’s financials reveals some challenges. The
company has reported a revenue growth decline of -3.50% and a negative EPS of -1.20,
reflecting some underlying financial headwinds. Additionally, the return on equity
stands at -3.64%, which may raise concerns about the company’s profitability in 
the near term.

Despite these hurdles, Perrigo’s robust free cash flow of approximately $379.5 million
offers a silver lining, suggesting that the company maintains a healthy liquidity
position to weather any short-term financial challenges. Moreover, with a generous
dividend yield of 4.41% and a notably high payout ratio of 10,950%, income-focused
investors might find Perrigo’s stock attractive for its dividend returns, although
the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such a high payout ratio should be scrutinized.

From a technical perspective, the stock’s 50-day and 200-day moving averages are
closely aligned at $26.44 and $26.39, respectively, indicating neutral momentum.
However, the Relative Strength Index (RSI) at 22.32 suggests that the stock is currently
oversold, which could present a buying opportunity if market conditions align favorably.

Analyst sentiment on Perrigo remains mixed, with three buy ratings and three hold
ratings, but importantly, no sell ratings, reflecting cautious optimism about the
company’s future prospects. Given the company’s strategic focus on consumer self-
care, including products ranging from pain relievers to oral care and women’s health
products, Perrigo is well-positioned to capitalize on the growing demand for self-
care and wellness solutions globally.

For investors seeking exposure to the healthcare sector with a focus on consumer
health products, Perrigo Company plc offers a compelling case. While the stock presents
some near-term financial challenges, its potential upside and solid dividend yield
make it a stock worth watching in the coming quarters. As always, investors should
conduct thorough due diligence and consider their risk tolerance when evaluating
investment opportunities in dynamic sectors like healthcare.

Share on: